Abstract
Serological probes have a long history in the study of cancer cells (Old 1981). Conventional serological analysis had to rely on polyclonal antibodies, and this proved to be a drawback in particular for the characterization of human cancer cells. Polyclonal antisera might contain antibodies of unrelated specificity in addition to the desired antibody. A general procedure for the production of monoclonal antibodies of defined specificity, first described by Köhler and Milstein (1975), revolutionized the serological and biochemical analysis of human cancer. Monoclonal antibodies can recognize a single antigenic determinant in a mixture of antigens. Furthermore, they can be produced in great quantities and in reproducible lots, thus permitting largescale production for practical applications. Applying this methodology, a number of well characterized tumor-restricted antigens have been defined (for reviews see Lloyd 1983; Sell and Reisfeld 1985), some of which belong structurally to the group of glycolipids (Hakamori 1985; Feizi 1985). Gangliosides represent a subgroup of glycolipids and some of these (GD3, GD2, GM2, according to the classification of Svennerholm) are recognized as tumor-associated antigens for neuroectodermal tumors.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Cahan LD, Irie RF, Singh R, Cassidenti A, Paulson JC (1982) Identification of a human neuroectodermal tumor antigen (OFA-1-2) as ganglioside GD2. Proc Natl Acad Sci USA 79:7629–7633
Cheresh DA, Harper JR, Schulz G, Reisfeld RA (1984) Localization of the gangliosides GD2 and GD3 in adhesion plaques and on the surface of human melanoma cells. Proc Natl Acad Sci USA 81:5767–5771
Cheresh DA, Honsik CJ, Staffileno LK, Jung G, Reisfeld RA (1985) Disialoganglioside GD3 on human melanoma serves as a relevant target antigen for monoclonal antibody-mediated tumor cytolysis. Proc Natl Acad Sci USA 82:5155–5159
Cheung N-K, Berger N, Coccia P, Kallick S, Lazarus H, Miraldi F, Saarinen U, Strandjord S (1986) Murine monoclonal antibody specific for GD2 ganglioside: a phase I trial in patients with neuroblastoma, melanoma and osteogenic sarcoma. Proc AACR:1260
Dippold WG, Lloyd KO, Li LTC, Ikeda H, Oettgen HF, Old LJ (1980) Cell surface antigens of human malignant melanoma: definition of six antigenic systems with monoclonal antibodies. Proc Natl Acad Sci USA 77:6114–6118
Dippold WG, Knuth A, Meyer zum Büschenfelde K-H (1984a) Inhibition of human melanoma cell growth in vitro by monoclonal anti-GD3-ganglioside antibody. Cancer Res 44:806–810
Dippold WG, Knuth A, Meyer zum Büschenfelde K-H (1984b) Melanoma antibodies: specificity and interaction with melanoma and cytotoxic T-cells. Behring Inst Mitt 74:14–18
Dippold WG, Dienes HP, Knuth A, Meyer zum Büschenfelde K-H (1985a) Immunohistochemical localization of ganglioside GD3 in human malignant melanoma, epithelial tumors, and normal tissues. Cancer Res 45:3699–3705
Dippold WG, Knuth A, Meyer zum Büschenfelde K-H (1985b) Inflammatory tumor response to monoclonal antibody infusion. Eur J Cancer Clin Oncol 21:907–912
Feizi T (1985) Carbohydrate antigens in human cancer. Cancer Surv 4:245–269
Hakomori S (1985) Aberrant glycosylation in cancer cell membranes as focussed on glycolipids: overview and perspectives. Cancer Res. 45:2405–2414
Hellström I, Brankovan V, Hellström KE (1985) Strong antitumor activities of IgG3 antibodies to a human melanoma-associated ganglioside. Proc Natl Acad Sci USA 82:1499–1502
Honsik CJ, Jung G, Reisfeld RA (1986) Lymphokine-activated killer cells targeted by monoclonal antibodies to the disialogangliosides GD2 and GD3 specifically lyse human tumor cells of neuroectodermal origin. Proc Natl Acad Sci USA 82:7893–7897
Houghton AN, Mintzer D, Cordon-Cardo C, Welt S, Fliegel B, Vadhan S, Carswell E, Melamed MR, Oettgen HF, Old LJ (1985) Mouse monoclonal antibody detecting GD3 ganglioside; a phase I trial in patients with malignant melanoma. Proc Natl Acad Sci USA 82:1242–1246
Houghton AN, Vadhan S, Wong G, Yeh S, Cordon-Cardo C, Chapman P, Richards E, Dantis L, Welt S, Melamed M, Oettgen HF, Old LJ (1986) Clinical study of a mouse monoclonal antibody directed against GD3 ganglioside in patients with melanoma. Proc ASCO:906
Irie RF, Sze LL, Saxton RE (1982) Human antibody to OFA-1, a tumor antigen, produced in vitro by Epstein-Barr virus-transformed human B lymphoid cell lines. Proc Natl Acad Sci USA 79:5666–5670
Knuth A, Dippold WG, Houghton AN, Meyer zum Büschenfelde K-H, Oettgen HF, Old LJ (1984a) ADCC reactivity of human melanoma cells with mouse monoclonal antibodies. Proc AACR 25:1005
Knuth A, Dippold WG, Meyer zum Büschenfelde K-H (1984b) Target level blocking of T-cell cytotoxicity for human malignant melanoma by monoclonal antibodies. Cell Immunol 83:398–403
Knuth A, Dippold WG, Meyer zum Büschenfelde K-H (1985) Disialoganglioside GD3-specific monoclonal antibody in ADCC for human malignant melanoma. In: Bagnara J, Klaus SN, Paul E, Schartl M (eds) Biological, molecular and clinical aspects of pigmentation. University of Tokyo Press, Tokyo, pp 421–424
Köhler G, Milstein C (1975) Continuous culture of fused cells secreting antibody of predefined specificity. Nature 256:495–496
Lingwood CA, Hakomori S (1977) Selective inhibition of cell growth and associated changes in glycolipid metabolism induced by monovalent antibodies to glycolipids. Exp Cell Res 108:385–391
Lloyd KO (1983) Human tumor antigens. Detection and characterization with mouse monoclonal antibodies. In: Herberman RB (ed) Basic and clinical tumor immunology. Nijhoff, Boston, pp 159–214
Old LJ (1981) Cancer immunology: The search for specificity. GHA Clowes Memorial Lecture. Cancer Res 41:361–375
Pukel CS, Lloyd KO, Travassos LT, Dippold WG, Oettgen HF, Old LJ (1982) GD3 — a prominent ganglioside of human melanoma: detection and characterization by mouse monoclonal antibody. J Exp Med 155:1133–1147
Saito M, Yu RK, Cheung N-K (1985) V. Ganglioside GD2 specificity of monoclonal antibodies to human neuroblastoma cells. Biochem Biophys Res Commun 127:1–7
Schulz G, Cheresh DA, Varki NM, Yu A, Staffileno LK, Reisfeld RA (1984) Detection of ganglioside GD2 in tumor tissues and sera of neuroblastoma patients. Cancer Res 44:5914–5920
Sell S, Reisfeld RA (1985) Monoclonal antibodies in cancer: contemporary biomedicine. Humana, Clifton, NJ, pp 1–485
Vogel C-W, Welt SW, Carswell EA, Old LJ, Müller-Eberhard HJ (1983) A murine IgG3 monoclonal antibody to a melanoma antigen that activates complement in vitro and in vivo. Immunobiology 164:309
Watanabe T, Pukel C, Takeyama H, Lloyd KO, Shiku H, Li LTC, Travassos LR, Oettgen HF, Old LJ (1982) Human melanoma antigen AH is an autoantigenic ganglioside related to GD2. J Exp Med 155:1884–1889
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1989 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
Dippold, W.G., Bernhard, H., Dienes, H.P., Meyer zum Büschenfelde, KH. (1989). Functional Properties and Application of Ganglioside Antibodies to Patients with Malignant Melanoma. In: Drahovsky, D., Kornhuber, B. (eds) Human Malignancies. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-73642-1_9
Download citation
DOI: https://doi.org/10.1007/978-3-642-73642-1_9
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-19219-0
Online ISBN: 978-3-642-73642-1
eBook Packages: Springer Book Archive